[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519202":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":24,"locations":18,"responsibleParty":30,"collaborators":32,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":18,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":18,"studyType":48,"phases":49,"briefSummary":40,"conditions":51,"keywords":18,"overallStatus":53,"whyStopped":18,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":18},{"fullName":5,"class":6},"StemCyte International, Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"A group: hUCB treatment","EXPERIMENTAL","Human cord blood infusion",[13],"Biological: hUCB",{"label":15,"type":16,"description":17,"interventionNames":18},"B group: Placebo treatment","NO_INTERVENTION","Placebo infusion",null,[20],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":18},"BIOLOGICAL","hUCB",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Ying Chieh Bobo Chen, PhD","CONTACT","02-26013013 Ext809","bobo.chen@stemcyte.com.tw",{"type":31,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[33],{"name":34,"class":6},"StemCyte Taiwan Co., Ltd.","100519202","phase-2-human-umbilical-cord-blood-infusion-in-patients-with-acute-ischemic-stroke-ais-100519202",false,"NCT06040476","Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)","A Phase II, Randomized, Double-blind, Parallel, Placebo-controlled Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke","Inclusion Criteria:\n\n* Male or female subject ≥18 and ≤80 years of age.\n* Subject with a confirmed diagnosis of AIS and hemiplegia\n\nExclusion Criteria:\n\n* Subject with known immune disease, immunodeficiency, or receives immunosuppressive therapy\u002Fimmunomodulators within 4 weeks or 5 half-lives prior to screening, whichever is longer.","ALL","18 Years","80 Years",{"count":46,"type":47},39,"ESTIMATED","INTERVENTIONAL",[50],"PHASE2",[52],"Acute Ischemic Stroke","NOT_YET_RECRUITING","2025-02-25",{"date":56,"type":57},"2025-02-27","ACTUAL",{"date":59,"type":47},"2025-09",{"date":61,"type":47},"2028-08",{"name":63,"class":6},"StemCyte, Inc."]